Last reviewed · How we verify

NCT05768867: FRAPEYQUEST

French Translation and Validation of the PEYronie's Disease QUESTionnaire

Completed Last updated 27 August 2024
What this trial tests

trial testing FRAnçaise du PEYronie's Disease QUESTionnaire in Peyronie Disease in 30 participants. Completed in 22 May 2023.

Timeline
6 March 2023
Primary endpoint
22 May 2023
22 May 2023

Quick facts

Lead sponsorUniversity Hospital, Toulouse
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date6 March 2023
Primary completion22 May 2023
Estimated completion22 May 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

18 and older, male only, with Peyronie Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective cohort dedicated to peyronie's disease. The aim is to validate the french translation of the peyronie's disease questionnaire. The primary endpoint is the response rate to the questionnaire.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Peyronie Disease

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05768867.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing